Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin

References

• Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011;29:1924–33
   PubMed Web of Science ®Google Scholar
• Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener 2014;3:19
   PubMedGoogle Scholar
• Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015;86:1036–43
   PubMed Web of Science ®Google Scholar
• Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, Obici L, et al. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 2014;35:E2403–12
   PubMed Web of Science ®Google Scholar
• Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160–84
   PubMed Web of Science ®Google Scholar
• Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8:31
   PubMed Web of Science ®Google Scholar
• Westermark P, Sletten K, Johansson B, Cornwell GG. III Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. U.S.A. 1990;87:2843–5
   PubMed Web of Science ®Google Scholar
• Sikora JL, Logue MW, Chan GG, Spencer BH, Prokaeva TB, Baldwin CT, Seldin DC, et al. Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt). Hum Genet 2015;134:111–21
   PubMed Web of Science ®Google Scholar
• Coehlo T, Erikson BG, Falk R, Grogan D, Ikeda SI, Mauer M, Planté-Bordeneuve V, et al. A physician's guide to transthyretin amyloidosis. Amyloidosis Foundation; c2008
   Google Scholar
• Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113–16
   PubMed Web of Science ®Google Scholar
• Bulawa CE, Connelly S, DeVit M, Wang L, Weigel C, Fleming JA, Packman J, et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. U.S.A. 2012;109:9629–34
   PubMed Web of Science ®Google Scholar
• Coelho T, Maia LF, Martins da Silva A, Waddington CM, Planté-Bordeneuve V, Lozeron P, Suhr OB, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785–92
   PubMed Web of Science ®Google Scholar
• Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. Jama 2013;310:2658–67
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, Perez J, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369:819–29
   PubMed Web of Science ®Google Scholar
• Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012;19:43–4
   PubMed Web of Science ®Google Scholar
• Arsequell G, Planas A. Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands. Curr Med Chem 2012;19:2343–55
   PubMed Web of Science ®Google Scholar
• Kanai M, Raz A, Goodman DS. Retinol-binding protein: the transport protein for vitamin A in human plasma. J Clin Invest 1968;47:2025–44
   PubMed Web of Science ®Google Scholar
• Jiang X, Buxbaum JN, Kelly JW. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA. 2001;98:14943–8
   PubMed Web of Science ®Google Scholar
• Kelly JW. Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 1996;6:11–17
   PubMed Web of Science ®Google Scholar
• De Genst E, Messer A, Dobson CM. Antibodies and protein misfolding: from structural research tools to therapeutic strategies. Biochim Biophys Acta 2014;1844:1907–19
   PubMed Web of Science ®Google Scholar
• Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, Macy S, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One 2012;7:e52686
   PubMed Web of Science ®Google Scholar
• Obayashi K, Tasaki M, Jono H, Ueda M, Shinriki S, Misumi Y, Yamashita T, et al. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine. Clin Chim Acta 2013;419:127–31
   PubMed Web of Science ®Google Scholar
• Planque SA, Nishiyama Y, Hara M, Sonoda S, Murphy SK, Watanabe K, Mitsuda Y, et al. Physiological IgM class catalytic antibodies selective for transthyretin amyloid. J Biol Chem 2014;289:13243–58
   PubMed Web of Science ®Google Scholar
• Terazaki H, Ando Y, Fernandes R, Yamamura K, Maeda S, Saraiva MJ. Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest 2006;86:23–31
   PubMed Web of Science ®Google Scholar
• Gustavsson Å, Engström U, Westermark P. Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations. Am J Pathol 1994;144:1301–11
   PubMed Web of Science ®Google Scholar
• Redondo C, Damas AM, Saraiva MJM. Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity. Biochem J 2000;348:167–72
   PubMed Web of Science ®Google Scholar
• Phay M, Blinder V, Macy S, Greene MJ, Wooliver DC, Liu W, Planas A, et al. Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils. Rejuvenation Res 2014;17:97–104
   PubMed Web of Science ®Google Scholar
• Su Y, Jono H, Torikai M, Hosoi A, Soejima K, Guo J, Tasaki M, et al. Antibody therapy for familial amyloidotic polyneuropathy. Amyloid 2012;19:45–6
   PubMed Web of Science ®Google Scholar
• Goldsteins G, Persson H, Andersson K, Olofsson A, Dacklin I, Edvinsson Å, Saraiva MJ, et al. Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proc. Natl. Acad. Sci. U.S.A. 1999;96:3108–13
   PubMed Web of Science ®Google Scholar
• Redondo C, Damas AM, Olofsson A, Lundgren E, Saraiva MJM. Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. J Mol Biol 2000;304:461–70
   PubMed Web of Science ®Google Scholar
• Hurshman Babbes AR, Powers ET, Kelly JW. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 2008;47:6969–84
   PubMed Web of Science ®Google Scholar
• Jiang X, Smith CS, Petrassi HM, Hammarström P, White JT, Sacchettini JC, Kelly JW. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 2001;40:11442–52
   PubMed Web of Science ®Google Scholar
• Schmidt ML, Robinson KA, Lee VM, Trojanowski JQ. Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. Am J Pathol 1995;147:503–15
   PubMed Web of Science ®Google Scholar
• Sun Y, Arslan PE, Won A, Yip CM, Chakrabartty A. Binding of TDP-43 to the 3'UTR of its cognate mRNA enhances its solubility. Biochemistry 2014;53:5885–94
   PubMed Web of Science ®Google Scholar
• Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, Rydel RE. Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci 2005;25:1071–80
   PubMed Web of Science ®Google Scholar
• Xue W-F, Homans SW, Radford SE. Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc. Natl. Acad. Sci. U.S.A. 2008;105:8926–31
   PubMed Web of Science ®Google Scholar
• Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997;94:4109–12
   PubMed Web of Science ®Google Scholar
• Saelices L, Johnson LM, Liang WY, Sawaya MR, Cascio D, Ruchala P, Whitelegge J, et al. Uncovering the mechanism of aggregation of human transthyretin. J Biol Chem 2015;290:28932–43
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R, Burke R-L, Games D, Grajeda H, Guido T, et al. Peripherally administered antibodies against amyloid β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916–19
   PubMed Web of Science ®Google Scholar
• Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000;157:1239–46
   PubMed Web of Science ®Google Scholar
• Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 1979;38:284–93
   PubMed Web of Science ®Google Scholar
• Teixeira AC, Saraiva MJ. Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD. J Cell Mol Med 2013;17:429–35
   PubMed Web of Science ®Google Scholar
• Sekijima Y, Wiseman RL, Matteson J, Hammarström P, Miller SR, Sawkar AR, Balch WE, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005;121:73–85
   PubMed Web of Science ®Google Scholar
• Gertz M, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, et al. First in human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 2016; [Epub ahead of print]. DOI: 10.1200/JCO.2015.63.6530
   PubMed Web of Science ®Google Scholar
• Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286–300
   PubMed Web of Science ®Google Scholar